Nurix Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Nurix Therapeutics R&D Spending Growth & History (NRIX)
Nurix Therapeutics's r&d spending was $316.9M for fiscal 2025.
View full Nurix Therapeutics company overviewNurix Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | $316.9M | $95.3M | +42.99% |
| 2024 | 2024-11-30 | $221.6M | $32.5M | +17.17% |
| 2023 | 2023-11-30 | $189.1M | $4.7M | +2.52% |
| 2022 | 2022-11-30 | $184.5M | $68.1M | +58.46% |
| 2021 | 2021-11-30 | $116.4M | $49.9M | +75.10% |
| 2020 | 2020-11-30 | $66.5M | $21.5M | +47.68% |
| 2019 | 2019-11-30 | $45.0M | — | — |
Nurix Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | $87.7M | $9.6M | +12.24% |
| Q1 2026 | 2026-02-28 | $84.1M | $14.5M | +20.78% |
| Q4 2025 | 2025-11-30 | $83.0M | $15.8M | +23.50% |
| Q3 2025 | 2025-08-31 | $86.1M | $30.6M | +55.22% |
| Q2 2025 | 2025-05-31 | $78.1M | $29.2M | +59.63% |
| Q1 2025 | 2025-02-28 | $69.7M | $19.7M | +39.31% |
| Q4 2024 | 2024-11-30 | $67.2M | $17.5M | +35.22% |
| Q3 2024 | 2024-08-31 | $55.5M | $7.6M | +15.93% |
| Q2 2024 | 2024-05-31 | $48.9M | $3.2M | +6.90% |
| Q1 2024 | 2024-02-29 | $50.0M | $4.2M | +9.14% |
| Q4 2023 | 2023-11-30 | $49.7M | $3.6M | +7.82% |
| Q3 2023 | 2023-08-31 | $47.9M | $95,000 | +0.20% |
| Q2 2023 | 2023-05-31 | $45.8M | −$1.7M | −3.64% |
| Q1 2023 | 2023-02-28 | $45.8M | $2.7M | +6.21% |
| Q4 2022 | 2022-11-30 | $46.1M | $9.6M | +26.21% |
| Q3 2022 | 2022-08-31 | $47.8M | $16.9M | +54.54% |
| Q2 2022 | 2022-05-31 | $47.5M | $21.5M | +82.71% |
| Q1 2022 | 2022-02-28 | $43.1M | $20.1M | +87.53% |
| Q4 2021 | 2021-11-30 | $36.5M | $16.1M | +78.67% |
| Q3 2021 | 2021-08-31 | $30.9M | $12.0M | +63.19% |
| Q2 2021 | 2021-05-31 | $26.0M | $11.9M | +83.81% |
| Q1 2021 | 2021-02-28 | $23.0M | $10.0M | +77.40% |
| Q4 2020 | 2020-11-30 | $20.4M | — | — |
| Q3 2020 | 2020-08-31 | $18.9M | $7.9M | +72.05% |
| Q2 2020 | 2020-05-31 | $14.1M | — | — |
| Q1 2020 | 2020-02-29 | $13.0M | — | — |
| Q3 2019 | 2019-08-31 | $11.0M | — | — |
Nurix Therapeutics r&d spending trends
Over the last five fiscal years, Nurix Therapeutics's r&d spending increased from $66.5M to $316.9M, a change of $250.4M. The latest reported quarter, Q2 2026, shows $87.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nurix Therapeutics source filings ↗